Paying user area
Try for free
Illumina Inc. pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Illumina Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Free Cash Flow to The Firm (FCFF)
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
An analysis of the annual cash flow data over the five-year period reveals a generally positive trend in the company's cash generation capabilities.
- Net cash provided by operating activities
- This metric demonstrates a consistent increase from 2016 to 2018, rising from $687 million to $1,142 million, indicating improving operational efficiency or growth in core business activities. However, in 2019, there is a slight decline to $1,051 million, followed by a moderate rebound to $1,080 million in 2020. Despite the minor dip, the overall trend reflects sustained strong cash flows from operations.
- Free cash flow to the firm (FCFF)
- FCFF exhibits a steady upward trajectory throughout the entire period, starting at $427 million in 2016 and increasing to $891 million by 2020. The robust growth in FCFF suggests effective capital expenditure management relative to operating cash flows, resulting in enhanced financial flexibility and potential for value creation.
In summary, the data indicates that the company has strengthened its ability to generate cash from operations over the years, with free cash flow reflecting efficient use of capital resources. The slight variability in operating cash flows in later years does not detract from the overall positive liquidity position maintained by the company during this period.
Interest Paid, Net of Tax
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
2 2020 Calculation
Cash paid for interest, tax = Cash paid for interest × EITR
= × =
- Effective Income Tax Rate (EITR)
-
The effective income tax rate showed a notable fluctuation over the five-year period from 2016 to 2020. Initially, it decreased from 23.72% in 2016 to 20.61% in 2017, followed by a more pronounced decline to 11.3% in 2018. In 2019, the rate remained relatively stable, increasing slightly to 11.45%. In 2020, the effective tax rate rose significantly to 23.36%, nearly returning to its 2016 level.
This pattern suggests possible changes in the company’s tax strategies, tax law impacts, or variations in pre-tax earnings composition during this period. The sharp drop in tax rate in 2018 and 2019 may indicate utilization of tax benefits or credits, while the increase in 2020 could reflect reversal of these benefits or changes in income mix or tax regulations.
- Cash Paid for Interest, Net of Tax
-
No data is available for cash paid for interest, net of tax, across all years. This absence precludes any analysis of interest expense trends or related cash outflows.
Enterprise Value to FCFF Ratio, Current
Selected Financial Data (US$ in millions) | |
Enterprise value (EV) | |
Free cash flow to the firm (FCFF) | |
Valuation Ratio | |
EV/FCFF | |
Benchmarks | |
EV/FCFF, Competitors1 | |
AbbVie Inc. | |
Amgen Inc. | |
Bristol-Myers Squibb Co. | |
Danaher Corp. | |
Eli Lilly & Co. | |
Gilead Sciences Inc. | |
Johnson & Johnson | |
Merck & Co. Inc. | |
Pfizer Inc. | |
Regeneron Pharmaceuticals Inc. | |
Thermo Fisher Scientific Inc. | |
Vertex Pharmaceuticals Inc. | |
EV/FCFF, Sector | |
Pharmaceuticals, Biotechnology & Life Sciences | |
EV/FCFF, Industry | |
Health Care |
Based on: 10-K (reporting date: 2020-12-31).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Enterprise value (EV)1 | ||||||
Free cash flow to the firm (FCFF)2 | ||||||
Valuation Ratio | ||||||
EV/FCFF3 | ||||||
Benchmarks | ||||||
EV/FCFF, Competitors4 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
EV/FCFF, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
EV/FCFF, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
3 2020 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =
4 Click competitor name to see calculations.
- Enterprise Value (EV)
- The enterprise value demonstrated a consistent upward trend from 2016 to 2020. Starting at approximately $23.8 billion in 2016, it increased annually, reaching over $69.8 billion by the end of 2020. Notably, the most significant rise occurred between 2019 and 2020, where the EV grew by nearly 69%.
- Free Cash Flow to the Firm (FCFF)
- Free cash flow to the firm showed steady growth throughout the analyzed period. Beginning at $427 million in 2016, FCFF rose each year to reach $891 million in 2020. The growth was relatively stable, with no years of decline, indicating improved cash generation capabilities over time.
- EV to FCFF Ratio
- The ratio of enterprise value to free cash flow to the firm remained fairly consistent from 2016 through 2019, fluctuating slightly between approximately 49 and 56. However, in 2020, this ratio experienced a marked increase to 78.36. This suggests that while free cash flow grew moderately, enterprise value increased disproportionately, potentially implying a higher valuation multiple or market expectations of future growth that are not directly matched by cash flow.
- Overall Insights
- The data reveals a growing enterprise value alongside increasing free cash flow, which reflects positive operational performance and expanded market valuation. The sharp increase in EV during the final year analyzed, coupled with a significant rise in the EV/FCFF ratio, may indicate heightened investor optimism or strategic developments elevating perceived company value beyond its current cash flow metrics. This divergence warrants further investigation to understand the underlying drivers, including market conditions or corporate actions influencing valuation.